These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 10027195)
1. FDA treads delicate line between safety and speed. Oncology (Williston Park); 1999 Jan; 13(1):16. PubMed ID: 10027195 [No Abstract] [Full Text] [Related]
2. Patient group seeks overhaul of FDA clinical trial system in court. Hede K J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242 [No Abstract] [Full Text] [Related]
3. New FDA breakthrough-drug category--implications for patients. Darrow JJ; Avorn J; Kesselheim AS N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173 [No Abstract] [Full Text] [Related]
4. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval? Khozin S; Liu K; Jarow JP; Pazdur R Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722 [No Abstract] [Full Text] [Related]
7. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform. Rossen BR Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746 [TBL] [Abstract][Full Text] [Related]
8. New FDA breakthrough-drug category--implications for patients. Darrow JJ; Avorn J; Kesselheim AS N Engl J Med; 2014 Jul; 371(1):89-90. PubMed ID: 24988576 [No Abstract] [Full Text] [Related]
9. New FDA breakthrough-drug category--implications for patients. McClellan M; Sigal E N Engl J Med; 2014 Jul; 371(1):87-8. PubMed ID: 24988577 [No Abstract] [Full Text] [Related]
10. New FDA breakthrough-drug category--implications for patients. Murray BE N Engl J Med; 2014 Jul; 371(1):88. PubMed ID: 24988578 [No Abstract] [Full Text] [Related]
11. New FDA breakthrough-drug category--implications for patients. Velleca M N Engl J Med; 2014 Jul; 371(1):88-9. PubMed ID: 24988579 [No Abstract] [Full Text] [Related]
12. New FDA breakthrough-drug category--implications for patients. Ricart AD N Engl J Med; 2014 Jul; 371(1):89. PubMed ID: 24988580 [No Abstract] [Full Text] [Related]
13. Regulatory watch: FDA guidance on co-developing investigational drugs. Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094 [No Abstract] [Full Text] [Related]
14. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity. Fernandez DS; Huie JT Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155 [No Abstract] [Full Text] [Related]
15. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe. Roberts SA; Allen JD; Sigal EV Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577 [TBL] [Abstract][Full Text] [Related]
16. New office and new leader aim to streamline FDA cancer drug review process. Twombly R J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036 [No Abstract] [Full Text] [Related]
18. Balancing safety, effectiveness, and public desire: the FDA and cancer. Conti R Issue Brief (Commonw Fund); 2003 Apr; (615):1-6. PubMed ID: 12693391 [No Abstract] [Full Text] [Related]
19. Communicating with the FDA: the "third rail" of a new model for drug development. Stanski DR; Orloff JJ J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890 [No Abstract] [Full Text] [Related]
20. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move. Moss RW New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956 [No Abstract] [Full Text] [Related] [Next] [New Search]